Cervical screening test results associated with 265 histopathologic diagnoses of cervical glandular neoplasia

American Journal of Clinical Pathology

Volumn 140, Issue 1, 2013, Pages 47-54

  Zhao, Chengquan ^a   Li, Zaibo ^a   Austin, R Marshall ^a  

^a UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

Adenocarcinoma; AIS; Cervical glandular neoplasia; HPV; LBC; Pap cytology

Indexed keywords

ADENOSQUAMOUS CARCINOMA; ADULT; AGED; ARTICLE; CERVICAL GLANDULAR NEOPLASIA; FEMALE; HEALTH CARE SYSTEM; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; HYSTERECTOMY; MAJOR CLINICAL STUDY; PAPANICOLAOU TEST; PRIORITY JOURNAL; SCREENING TEST; TUMOR INVASION; UTERINE CERVIX BIOPSY; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA; UTERINE CERVIX CARCINOMA IN SITU; UTERINE CERVIX CYTOLOGY; WART VIRUS;

ADENOCARCINOMA; AIS; CERVICAL GLANDULAR NEOPLASIA; HPV; LBC; PAP CYTOLOGY;

ADENOCARCINOMA; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CARCINOMA IN SITU; CARCINOMA, ADENOSQUAMOUS; DNA, VIRAL; EARLY DETECTION OF CANCER; FEMALE; HUMAN PAPILLOMAVIRUS DNA TESTS; HUMANS; MIDDLE AGED; NEOPLASM INVASIVENESS; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; RETROSPECTIVE STUDIES; UTERINE CERVICAL NEOPLASMS; VAGINAL SMEARS; YOUNG ADULT;

EID: 84879427549     PISSN: 00029173     EISSN: 19437722     Source Type: Journal    
DOI: 10.1309/AJCPIP9M8HPVBSSC     Document Type: Article

References (64)

1. US Preventive Services Task Force. Screening for cervical cancer: recommendations and rationale. In: Guide to Clinical Preventive Services. 3rd ed. Rockville, MD: Agency for Healthcare Research and Quality; 2003.
2. Sasieni P, Castanon A, Cuzick J. Screening and adenocarcinoma of the cervix. Int J Cancer. 2009;125:525-529.
3. Gunnell AS, Ylitalo N, Sandin S, et al. A longitudinal Swedish study on screening for squamous cell carcinoma and adenocarcinoma: evidence of effectiveness and overtreatment. Cancer Epidemiol Biomarkers Prev. 2007;16:2641-2648.
4. Vizcaino AP, Moreno V, Bosch FX, et al. International trends in the incidence of cervical cancer, I: adenocarcinoma and adenosquamous carcinomas. Int J Cancer. 1998;75:536-545.
5. Hemminki K, Li X, Mutanen P. Age-incidence relationships and time trends in cervical cancer in Sweden. Eur J Epidemiol. 2001;17:323-328.
6. Liu S, Semenciew R, Probert A, et al. Cervical cancer in Canada: changing patterns in incidence and mortality. Int J Gynecol Cancer. 2001;11:24-31.
7. Adegoke O, Kulasingam S, Virnig B. Cervical cancer trends in the United States: a 35-year population-based analysis. J Womens Health (Larchmt). 2012;21:1031-1037.
8. Chan PG, Sung H-Y, Sawaya G. Changes in cervical cancer incidence after three decades of screening women less than 30 years old. Obstet Gynecol. 2003;102:765-773.
9. Smith HO, Tiffany MF, Qualls CR, et al. The rising incidence of adenocarcinoma relative to squamous cell carcinoma of the uterine cervix in the United States-a 24- year population-based study. Gynecol Oncol. 2000;78:97-105.
10. Bulk S, Visser O, Rozendaal L, et al. Incidence and survival rate of women with cervical cancer in the Greater Amsterdam area. Br J Cancer. 2003;89:834-839.
11. Bulk S, Visser O, Rozendaal L, et al. Cervical cancer in the Netherlands 1989-1998: decrease of squamous cell carcinoma in older women, increase of adenocarcinoma in younger women. Int J Cancer. 2005;113:1005-1009.
12. International Collaboration of Epidemiological Studies of Cervical Cancer. Comparison of risk factors for invasive squamous cell carcinoma and adenocarcinoma of the cervix: collaborative reanalysis of individual data on 8,097 women with squamous cell carcinoma and 1,374 women with adenocarcinoma from 12 epidemiological studies. Int J Cancer. 2006;120:885-891.
13. Pak SC, Martens M, Bekkers R, et al. Pap smear screening history of women with squamous cell carcinoma and adenocarcinoma of the cervix. Aust N Z J Obstet Gynaecol. 2007;47:504-507.
14. Castanon A, Ferryman S, Patnick J, et al. Review of cytology and histopathology as part of the NHS Cervical Screening Programme audit of invasive cervical cancers. Cytopathology. 2012;23:13-22.
15. Janerich DT, Hadjimichael O, Schwartz PE, et al. The screening histories of women with invasive cervical cancer, Connecticut. Am J Public Health. 1995;81:791-794.
16. Ashfaq R, Gibbons D, Vela C, et al. ThinPrep Pap test: accuracy for glandular disease. Acta Cytol. 1999;43:81-85.
17. Guidos BJ, Selvaggi SM. Detection of endometrial adenocarcinoma with the ThinPrep Pap test. Diagn Cytopathol. 2000;23:260-265.
18. Katki HA, Kinney WF, Lorey T, et al. Cervical cancer risk for women undergoing concurrent testing for human papillomavirus and cervical cytology: a population-based study in routine clinical practice. Lancet Oncol. 2011;12:663-672.
19. Kinney WF, Fetterman B, Cox JT, et al. Characteristics of 44 cervical cancers diagnosed following Pap-negative, high risk HPV-positive screening in routine clinical practice. Gynecol Oncol. 2011;121:309-313.
20. Solomon D, Davey D, Kurman R, et al. The 2001 Bethesda System: terminology for reporting results of cervical cytology. JAMA. 2002;287:2114-2119.
21. Davey E, d'Assuncao J, Irwig L, et al. Accuracy of reading liquid based cytology slides using the ThinPrep Imager compared with conventional cytology: prospective study. BMJ. 2007;335:31.
22. US Census Bureau. American Community Survey (ACS) website. 2010. http://www.census.gov/acs/www.Accessed December 16, 2012.
23. Austin RM, Onisko A, Druzdel M. The Pittsburgh cervical cancer screening model: a risk assessment tool. Arch Pathol Lab Med. 2010;134:744-750.
24. Zhao C, Austin RM. Human papillomavirus DNA detection in ThinPrep Pap test vials is independent of cytologic sampling of the transformation zone. Gynecol Oncol. 2007;107:231-235.
25. Zhao C, Austin RM. Adjunctive high-risk human papillomavirus DNA testing is a useful option for disease risk assessment in patients with negative Papanicolaou tests without an endocervical/transformation zone sample. Cancer Cytopathol. 2008;114:242-248.
26. Zhao C, Florea A, Onisko A, et al. Histologic follow-up results in 662 patients with Pap test findings of atypical glandular cells: results from a large academic womens hospital laboratory employing sensitive screening methods. Gynecol Oncol. 2009;114:383-389.
27. Zhao C, Florea A, Austin RM. Clinical utility of adjunctive high-risk HPV DNA testing in women with Pap test findings of atypical glandular cells. Arch Pathol Lab Med. 2010;134:103-108.
28. Armah H, Austin RM, Dabbs D, et al. Follow-up findings for women with human papillomavirus-positive and atypical squamous cells of undetermined significance screening test results in a large women's hospital practice. Arch Pathol Lab Med. 2009;133:1426-1430.
29. Zhao C, Elishaev E, Yuan KH, et al. Very low human papillomavirus DNA prevalence in mature women with negative computer-imaged liquid-based Pap tests. Cancer. 2007;111:292-297.
30. Bansal M, Austin RM, Zhao C. High-risk HPV DNA detected in less than 2% of over 25,000 cytology negative imaged liquid-based Pap test samples from women 30 and older. Gynecol Oncol. 2009;115:257-261.
31. Zhao C, Zhao S, Heider A, et al. Significance of highrisk HPV DNA detection in women 50 and older with squamous cell Pap test abnormalities. Arch Pathol Lab Med. 2010;134:1130-1135.
32. Heider A, Austin RM, Zhao C. HPV test results stratify risk for histopathologic follow-up findings of high-grade cervical intra-epithelial neoplasia in women with low-grade squamous intra-epithelial lesion Pap results. Acta Cytol. 2011;55:48-53.
33. Zhao C, Kalposi-Novak P, Austin RM. Follow-up findings in adolescents with HSIL Pap test results. Arch Pathol Lab Med. 2011;135:361-364.
34. Zhao C, Chen X, Onisko A, et al. Follow-up outcomes for a large cohort of U.S. women with negative imaged liquid-based cytology findings and positive high risk human papillomavirus test results. Gynecol Oncol. 2011;122:291-296.
35. Gao FF, Austin RM, Zhao C. Histopathologic follow-up and human papillomavirus DNA test results in 290 patients with high-grade squamous intraepithelial lesion Papanicolaou test results. Cancer Cytopathol. 2011;119:377-386.
36. Li Z, Austin RM, Guo M, et al. Screening test results associated with cancer diagnoses in 287 with cervical squamous carcinoma. Arch Pathol Lab Med. 2012;136:1533-1540.
37. Cohen D, Austin RM, Gilbert C, et al. Follow-up outcomes in a large cohort of patients with human papillomavirus-negative ASC-H cervical screening test results. Am J Clin Pathol. 2012;138:517-552.
38. Zhao C, Amin M, Weng B, et al. Cytology and human papillomavirus screening test results associated with 2827 histopathologic cervical intraepithelial neoplasia 2/3 diagnoses [published online October 10, 2012]. Arch Pathol Lab Med.
39. Zhao C, Weng B, Li Z, et al. Follow-up outcomes of a large cohort of low-risk women with negative imaged liquid-based cytology and negative HPV test results. Am J Clin Pathol. 2013;139:32-38.
40. Terry G, Ho L, Londesborough P, et al. Detection of highrisk HPV types by the hybrid capture 2 test. J Med Virol. 2001;65:155-162.
41. Crum CP. Laboratory management of CIN 2: the consensus is consensus. Am J Clin Pathol. 2008;130:162-164.
42. INK4a testing significantly increases accuracy in diagnosing highgrade cervical intraepithelial neoplasia. Am J Clin Pathol. 2010;133:395-406.
43. Plaxe SC, Saltstein SL. Estimation of the duration of the preclinical phase of cervical adenocarcinoma suggests that there is ample opportunity for screening. Gynecol Oncol. 1999;75:55-61.
44. Mitchell H, Hocking J, Saville M. Cervical cytology screening history of women diagnosed with adenocarcinoma in situ of the cervix: a case-controlled study. Acta Cytol. 2004;48:595-600.
45. Syrjanen K. Is improved detection of adenocarcinoma in situ by screening a key to reducing the incidence of cervical adenocarcinoma? Acta Cytol. 2004;48:591-594.
46. Mitchell H, Hocking J, Saville M. Improvement in protection against adenocarcinoma of the cervix resulting from participation in cervical screening. Cancer Cytopathol. 2003;99:336-341.
47. Luke C, Nguyen AM, Heard A. Benchmarking epidemiological characteristics of cervical cancer in advance of change in screening practice and commencement of vaccination. Austr N Z J Public Health. 2007;31:149-154.
48. Kinney W, Sawaya GF, Sung HY, et al. Stage at diagnosis and mortality in patients with adenocarcinoma and adenosquamous carcinoma of the uterine cervix diagnosed as a consequence of cytology. Acta Cytol. 2003;47:167-171.
49. Stuart GCE, McGregor SE, Duggan MA, et al. Review of the screening history of Alberta women with invasive cervical cancer. Can Med Assoc J. 1997;157:513-519.
50. Kalir T, Simsir A, Demopulos HB, et al. Obstacles to the early detection of endocervical adenocarcinoma. Int J Gyn Pathol. 2005;24:399-403.
51. Sherman ME, Dasgupta A, Schiffman M, et al. The Bethesda Interobserver Reproducibility Study (BIRST): a web-based assessment of the Bethesda System for classifying cervical cytology. Cancer Cytopathol. 2007;111:15-25.
52. Lickrish GM, Colgan TJ, Wright VC. Colposcopy of adenocarcinoma in situ and invasive adenocarcinoma of the uterine cervix. Obstet Gynecol Clin North Am. 1993;20:111-122.
53. Zaino R. Symposium part I: adenocarcinoma in situ, glandular dysplasia, and early invasive adenocarcinoma of the uterine cervix. Int J Gynecol Pathol. 2002;21:314-326.
54. Austin RM, Zhao C. Observations on Pap test litigation. Pathol Case Rev. 2011;16:73-82.
55. Schwartz PE, Hadjimichael O, Lowell DM, et al. Rapidly progressive cervical cancer: the Connecticut experience. Am J Obstet Gynecol. 1996;175:1105-1109.
56. Hildesheim A, Hadjimichael O, Schwartz PE, et al. Risk factors for rapid-onset cervical cancer. Am J Obstet Gynecol. 1999;180:571-577.
57. Herbert A, Singh N, Smith JAE. Adenocarcinoma of the uterine cervix compared with squamous cell carcinoma: a 12-year study in Southampton and South-west Hampshire. Cytopathology. 2001;12:26-36.
58. Sasieni P, Adams J. Changing rates of adenocarcinoma and adenosquamous carcinoma of the cervix in England. Lancet. 2001;357:1490-1493.
59. Austin RM, Zhao C. Type 1 and 2 cervical cancers: some cervical cancers are more difficult to prevent with screening. Cytopathology. 2012;23:6-12.
60. Sasieni P, Castanon A, Cuzick J. Effectiveness of cervical screening with age: population-based case-control study of prospectively recorded data. BMJ. 2009;339:b2968.
61. Carozzi FM, Tornesello MJ, Burroni E, et al. Prevalence of human papillomavirus types in high-grade cervical intraepithelial neoplasia and cancer in Italy. Cancer Epidemiol Biomarkers Prev. 2010;19:2389-2400.
62. Saslow D, Solomon S, Lawson HW, et al. American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. Am J Clin Pathol. 2012;137:516-542.
63. Committee on Practice Bulletins-Gynecology. ACOG practice bulletin number 131: screening for cervical cancer. Obstet Gynecol. 2012;120:1222-1238.
64. Zhao C, Chen X, Onisko A, et al. Analysis of 70,123 cases with negative Pap test and positive high-risk HPV co-test results in a large women's hospital [ASC Abstract 68]. Cyto Journal. 2011;8:S53-S54.